Perimenopause Symptom Management is Never One-Size-Fits-All, Says Menopause Expert
TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"
Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk
Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.
Oral Semaglutide 25 mg Shows Cardiometabolic Benefits Beyond Weight Loss in OASIS 4 Analysis
Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.
Precision Medicine Protocol for Cognitive Decline May Also Reduce Depression: Daily Dose
Your daily dose of the clinical news you may have missed.
Lumateperone Gets FDA Nod as Adjunctive Therapy for Major Depressive Disorder
As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.
Wegovy Users More Likely to Reach Key Obesity Treatment Targets, STEP UP Study Finds
Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.
Moderate-to-Severe OSA Linked to Doubled Risk of Brain Microbleeds Over 8 Years: New Research
New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.
5 Novel Mechanisms Reshaping Atopic Dermatitis Treatment and the Phase 2-3 Clinical Trials That Support Them
Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.
The Hidden Toll of Diabetes in the Workplace: Global Survey Data
Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.
FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy
The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.
Complementary Studies Point to How to Boost CRC Screening Rates
Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.
Blood Glucose Levels in T2D: 42 Factors that Make A Difference
These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
Tirzepatide Found to Lower A1C, BMI in Children and Adolescents with T2D: Daily Dose
FAQs on Cardiac Rehab in Women for Primary Care Clinicians
Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.
Lisa Larkin, MD: Elinzanetant Offers a “Game-Changing” Option for Menopause Care in Primary Care
Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.
Facility-Based CRC Screening Nearly 10-Fold Higher in 45- to 49-Year-Olds After Guideline Changes
Colorectal cancer screenings for 45- to 49-year-olds surge nearly tenfold after new guidelines, highlighting significant shifts in public health practices.
FDA Approves New Treatment for Acromegaly: Daily Dose
Perimenopausal Brain Fog: A Frequent Complaint That Needs a Compassionate Response, Says Marla Shapiro, CM, CCFP, MHSc
"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.
GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk
The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.
Tezepelumab Achieves Dual Benefit in Severe Asthma, Improving Control with Reduced Steroid Dependence
WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.
EPIC-Norfolk Study Supports Universal Screening for Three Cardiovascular Biomarkers
Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.
Quiz: Recent Advances in Menopause and Midlife Women’s Health Research
A quick quiz covering new research on menopause hormone therapy, Alzheimer risk, tirzepatide weight loss, and estetrol’s cardiovascular safety.
Aggressive Risk Factor Management Reduced Recurrent AF by Nearly Half After Catheter Ablation
The rate of AF recurrence was reduced significantly and participants also experienced improvements in self-reported AF severity as well as improved cardiometabolic measures.
Genitourinary Syndrome of Menopause (GSM): Clinical FAQ for Primary Care
Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.
Screening for Breast Cancer in Patients With Dense Breast Tissue: A Q&A With Donna Plecha, MD
TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.
US Obesity Rates Decline in Tandem With Rise in Use of GLP-1 RA, New Gallup Index Shows
Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.
TMS 2025: Regina Castaneda, MD, on Tirzepatide, Menopause, and Hormone Therapy
Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control
The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.
Inequities in MHT Prescribing Run Deep: A Conversation With Wake Forest's Anna Caroline Cochrane, MD
TMS 2025: Cochrane explains the impetus behind 2 studies she has authored on the patient- and provider-level factors that influence MHT prescribing.
Mayo Clinic Researcher on How Hormone Therapy May Influence Weight Loss Outcomes With Tirzepatide
